Silence Therapeutics

About:

Silence Therapeutics is a drug development company with a proprietary genetic medicine platform.

Website: http://www.silence-therapeutics.com

Twitter/X: silencetheraplc

Top Investors: TCG Crossover, Frazier Life Sciences, Great Point Partners, Redmile Group, Vivo Capital

Description:

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.

Total Funding Amount:

$249M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

London, England, United Kingdom

Founded Date:

1999-01-01

Contact Email:

info(AT)silence-therapeutics.com

Founders:

Number of Employees:

101-250

Last Funding Date:

2024-02-02

IPO Status:

Public

Industries:

© 2025 bioDAO.ai